1
|
Ortega Suero G, Abenza Abildúa MJ, Serrano Munuera C, Rouco Axpe I, Arpa Gutiérrez FJ, Adarmes Gómez AD, Rodríguez de Rivera FJ, Quintans Castro B, Posada Rodríguez I, Vadillo Bermejo A, Domingo Santos Á, Blanco Vicente E, Infante Ceberio I, Pardo Fernández J, Costa Arpín E, Painous Martí C, Muñoz JE, Mir Rivera P, Montón Álvarez F, Bataller Alberola L, Gascón Bayarri J, Casasnovas Pons C, Vélez Santamaría V, López de Munain A, Fernández-Eulate G, Gazulla Abío J, Sanz Gallego I, Rojas Bartolomé L, Ayo Martín Ó, Segura Martín T, González Mingot C, Baraldés Rovira M, Sivera Mascaró R, Cubo Delgado E, Echavarría Íñiguez A, Vázquez Sánchez F, Bártulos Iglesias M, Casadevall Codina MT, Martínez Fernández EM, Labandeira Guerra C, Alemany Perna B, Carvajal Hernández A, Fernández Moreno C, Palacín Larroy M, Caballol Pons N, Ávila Rivera A, Navacerrada Barrero FJ, Lobato Rodríguez R, Sobrido Gómez MJ. Epidemiology of ataxia and hereditary spastic paraplegia in Spain: a cross-sectional study. Neurologia 2023:S2173-5808(23)00023-8. [PMID: 37120112 DOI: 10.1016/j.nrleng.2023.04.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Accepted: 01/01/2021] [Indexed: 05/01/2023] Open
Abstract
INTRODUCTION Ataxia and hereditary spastic paraplegia are rare neurodegenerative syndromes. We aimed to determine the prevalence of these disorders in Spain in 2019. PATIENTS AND METHODS We conducted a cross-sectional, multicentre, retrospective, descriptive study of patients with ataxia and hereditary spastic paraplegia in Spain between March 2018 and December 2019. RESULTS We gathered data from a total of 1933 patients from 11 autonomous communities, provided by 47 neurologists or geneticists. Mean (SD) age in our sample was 53.64 (20.51) years; 982 patients were men (50.8%) and 951 were women (49.2%). The genetic defect was unidentified in 920 patients (47.6%). A total of 1371 patients (70.9%) had ataxia and 562 (29.1%) had hereditary spastic paraplegia. Prevalence rates for ataxia and hereditary spastic paraplegia were estimated at 5.48 and 2.24 cases per 100 000 population, respectively. The most frequent type of dominant ataxia in our sample was SCA3, and the most frequent recessive ataxia was Friedreich ataxia. The most frequent type of dominant hereditary spastic paraplegia in our sample was SPG4, and the most frequent recessive type was SPG7. CONCLUSIONS In our sample, the estimated prevalence of ataxia and hereditary spastic paraplegia was 7.73 cases per 100 000 population. This rate is similar to those reported for other countries. Genetic diagnosis was not available in 47.6% of cases. Despite these limitations, our study provides useful data for estimating the necessary healthcare resources for these patients, raising awareness of these diseases, determining the most frequent causal mutations for local screening programmes, and promoting the development of clinical trials.
Collapse
Affiliation(s)
- G Ortega Suero
- Servicio de Neurología, Hospital Alcázar de San Juan, Complejo La Mancha-Centro, Ciudad Real, Spain
| | - M J Abenza Abildúa
- Servicio de Neurología, Hospital Universitario Infanta Sofía, Madrid, Spain.
| | | | - I Rouco Axpe
- Servicio de Neurología, Hospital Universitario de Cruces, Bilbao, Spain
| | - F J Arpa Gutiérrez
- Departamento de Anatomía, Histología y Neurociencia, Facultad de Medicina, Universidad Autónoma de Madrid, Asesoría Docente de Neurología, Hospital Clínico San Carlos, Madrid, Spain
| | - A D Adarmes Gómez
- Servicio de Neurología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | | | - B Quintans Castro
- Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, Spain
| | - I Posada Rodríguez
- Servicio de Neurología, Hospital Universitario 12 de Octubre, Madrid, Spain
| | - A Vadillo Bermejo
- Servicio de Neurología, Hospital Universitario Mancha Centro, Ciudad Real, Spain
| | - Á Domingo Santos
- Servicio de Neurología, Hospital G. Tomelloso, Ciudad Real, Spain
| | | | - I Infante Ceberio
- Servicio de Neurología, Hospital Universitario Marqués de Valdecilla, Cantabria, Spain
| | - J Pardo Fernández
- Servicio de Neurología, Hospital Clínico Santiago de Compostela, Galicia, Spain
| | - E Costa Arpín
- Servicio de Neurología, Hospital Clínico Santiago de Compostela, Galicia, Spain
| | - C Painous Martí
- Servicio de Neurología, Unidad de Neurogenética, Hospital Universitario Clinic, Barcelona, Spain
| | - J E Muñoz
- Servicio de Neurología, Unidad de Neurogenética, Hospital Universitario Clinic, Barcelona, Spain
| | - P Mir Rivera
- Servicio de Neurología, Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - F Montón Álvarez
- Servicio de Neurología, Hospital Nuestra señora de Candelaria, Tenerife, Spain
| | | | - J Gascón Bayarri
- Servicio de Neurología, Hospital Universitario Bellvitge, Barcelona, Spain
| | - C Casasnovas Pons
- Servicio de Neurología, Hospital Universitario Bellvitge, Barcelona, Spain
| | - V Vélez Santamaría
- Servicio de Neurología, Hospital Universitario Bellvitge, Barcelona, Spain
| | - A López de Munain
- Servicio de Neurología, Hospital Universitario Donostia, San Sebastián, Spain
| | - G Fernández-Eulate
- Servicio de Neurología, Hospital Universitario Donostia, San Sebastián, Spain
| | - J Gazulla Abío
- Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza, Spain
| | - I Sanz Gallego
- Servicio de Neurología, Hospital Universitario Sonsoles, Ávila, Spain
| | - L Rojas Bartolomé
- Servicio de Neurología, Hospital Universitario de Albacete, Albacete, Spain
| | - Ó Ayo Martín
- Servicio de Neurología, Hospital Universitario de Albacete, Albacete, Spain
| | - T Segura Martín
- Servicio de Neurología, Hospital Universitario de Albacete, Albacete, Spain
| | - C González Mingot
- Servicio de Neurología, Hospital Universitario Arnau de Vilanova, Lleida, Spain
| | - M Baraldés Rovira
- Servicio de Neurología, Hospital Universitario Arnau de Vilanova, Lleida, Spain
| | - R Sivera Mascaró
- Servicio de Neurología, Hospital Francesc de Borja, Gandía, Spain
| | - E Cubo Delgado
- Servicio de Neurología, Hospital Universitario de Burgos, Burgos, Spain
| | | | - F Vázquez Sánchez
- Servicio de Neurología, Hospital Universitario de Burgos, Burgos, Spain
| | | | | | | | - C Labandeira Guerra
- Servicio de Neurología, Hospital Universitario Álvaro Cunqueiro, Vigo, Spain
| | - B Alemany Perna
- Servicio de Neurología, Hospital Universitario Josep Trueta, Girona, Spain
| | - A Carvajal Hernández
- Servicio de Neurología, Hospital Universitario Virgen de las Nieves, Granada, Spain
| | | | | | - N Caballol Pons
- Sección de Neurología, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, Spain
| | - A Ávila Rivera
- Servicio de Neurología, Hospital General L´Hospitalet, Barcelona, Spain
| | | | - R Lobato Rodríguez
- Sección de Neurología, Hospital Universitario Infanta Sofía, Madrid, Spain
| | | |
Collapse
|
2
|
Ortega Suero G, Abenza Abildúa MJ, Serrano Munuera C, Rouco Axpe I, Arpa Gutiérrez FJ, Adarmes Gómez AD, Rodríguez de Rivera FJ, Quintans Castro B, Posada Rodríguez I, Vadillo Bermejo A, Domingo Santos Á, Blanco Vicente E, Infante Ceberio I, Pardo Fernández J, Costa Arpín E, Painous Martí C, Muñoz JE, Mir Rivera P, Montón Álvarez F, Bataller Alberola L, Gascón Bayarri J, Casasnovas Pons C, Vélez Santamaría V, López Munain A, Fernández García Eulate G, Gazulla Abío J, Sanz Gallego I, Rojas Bartolomé L, Ayo Martín Ó, Segura Martín T, González Mingot C, Baraldés Rovira M, Sivera Mascaró R, Cubo Delgado E, Echevarría Íñiguez A, Vázquez Sánchez F, Bártulos Iglesias M, Casadevall Codina MT, Martínez Fernández EM, Labandeira Guerra C, Alemany Perna B, Carvajal Hernández A, Fernández Moreno C, Palacín Larroy M, Caballol Pons N, Ávila Rivera A, Navacerrada Barrero FJ, Lobato Rodríguez R, Sobrido Gómez MJ. Epidemiology of ataxia and hereditary spastic paraplegia in Spain: a cross-sectional study. Neurologia 2021; 38:S0213-4853(21)00021-9. [PMID: 33775475 DOI: 10.1016/j.nrl.2021.01.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Accepted: 01/01/2021] [Indexed: 10/21/2022] Open
Abstract
INTRODUCTION Ataxia and hereditary spastic paraplegia are rare neurodegenerative syndromes. We aimed to determine the prevalence of these disorders in Spain in 2019. PATIENTS AND METHODS We conducted a cross-sectional, multicentre, retrospective, descriptive study of patients with ataxia and hereditary spastic paraplegia in Spain between March 2018 and December 2019. RESULTS We gathered data from a total of 1.809 patients from 11 autonomous communities, provided by 47 neurologists or geneticists. Mean (SD) age in our sample was 53.64 (20.51) years; 920 patients were men (50.8%) and 889 were women (49.2%). The genetic defect was unidentified in 920 patients (47.6%). A total of 1371 patients (70.9%) had ataxia and 562 (29.1%) had hereditary spastic paraplegia. Prevalence rates for ataxia and hereditary spastic paraplegia were estimated at 5.48 and 2.24 cases per 100 000 population, respectively. The most frequent type of dominant ataxia in our sample was SCA3, and the most frequent recessive ataxia was Friedreich ataxia. The most frequent type of dominant hereditary spastic paraplegia in our sample was SPG4, and the most frequent recessive type was SPG7. CONCLUSIONS In our sample, the estimated prevalence of ataxia and hereditary spastic paraplegia was 7.73 cases per 100 000 population. This rate is similar to those reported for other countries. Genetic diagnosis was not available in 47.6% of cases. Despite these limitations, our study provides useful data for estimating the necessary healthcare resources for these patients, raising awareness of these diseases, determining the most frequent causal mutations for local screening programmes, and promoting the development of clinical trials.
Collapse
Affiliation(s)
- G Ortega Suero
- Servicio de Neurología, Hospital Alcázar de San Juan, Complejo La Mancha-Centro, Ciudad Real, España
| | - M J Abenza Abildúa
- Servicio de Neurología, Hospital Universitario Infanta Sofía, Madrid, España.
| | - C Serrano Munuera
- Servicio de Neurología, Hospital Sant Joan de Déu, Martorell, España
| | - I Rouco Axpe
- Servicio de Neurología, Hospital Universitario de Cruces, Bilbao, España
| | - F J Arpa Gutiérrez
- Departamento de Anatomía, Histología y Neurociencia, Facultad de Medicina, Universidad Autónoma de Madrid, Asesoría Docente de Neurología, Hospital Clínico San Carlos, Madrid, España
| | - A D Adarmes Gómez
- Servicio de Neurología, Hospital Universitario Virgen del Rocío, Sevilla, España
| | - F J Rodríguez de Rivera
- Servicio de Neurología, Hospital Universitario La Paz-Carlos III-Cantoblanco, Madrid, España
| | - B Quintans Castro
- Fundación Pública Galega de Medicina Xenómica, Santiago de Compostela, España
| | - I Posada Rodríguez
- Servicio de Neurología, Hospital Universitario 12 de Octubre, Madrid, España
| | - A Vadillo Bermejo
- Servicio de Neurología, Hospital Universitario Mancha Centro, Ciudad Real, España
| | - Á Domingo Santos
- Servicio de Neurología, Hospital G. Tomelloso, Ciudad Real, España
| | - E Blanco Vicente
- Servicio de Neurología, Hospital Villarrobledo, Albacete, España
| | - I Infante Ceberio
- Servicio de Neurología, Hospital Universitario Marqués de Valdecilla, Cantabria, España
| | - J Pardo Fernández
- Servicio de Neurología, Hospital Clínico Santiago de Compostela, Galicia, España
| | - E Costa Arpín
- Servicio de Neurología, Hospital Clínico Santiago de Compostela, Galicia, España
| | - C Painous Martí
- Servicio de Neurología, Unidad de Neurogenética, Hospital Universitario Clinic, Barcelona, España
| | - J E Muñoz
- Servicio de Neurología, Unidad de Neurogenética, Hospital Universitario Clinic, Barcelona, España
| | - P Mir Rivera
- Servicio de Neurología, Hospital Universitario Virgen del Rocío, Sevilla, España
| | - F Montón Álvarez
- Servicio de Neurología, Hospital Nuestra señora de Candelaria, Tenerife, España
| | | | - J Gascón Bayarri
- Servicio de Neurología, Hospital Universitario Bellvitge, Barcelona, España
| | - C Casasnovas Pons
- Servicio de Neurología, Hospital Universitario Bellvitge, Barcelona, España
| | - V Vélez Santamaría
- Servicio de Neurología, Hospital Universitario Bellvitge, Barcelona, España
| | - A López Munain
- Servicio de Neurología, Hospital Universitario Donostia, San Sebastián, España
| | | | - J Gazulla Abío
- Servicio de Neurología, Hospital Universitario Miguel Servet, Zaragoza, España
| | - I Sanz Gallego
- Servicio de Neurología, Hospital Universitario Sonsoles, Ávila, España
| | - L Rojas Bartolomé
- Servicio de Neurología, Hospital Universitario de Albacete, Albacete, España
| | - Ó Ayo Martín
- Servicio de Neurología, Hospital Universitario de Albacete, Albacete, España
| | - T Segura Martín
- Servicio de Neurología, Hospital Universitario de Albacete, Albacete, España
| | - C González Mingot
- Servicio de Neurología, Hospital Universitario Arnau de Vilanova, Lleida, España
| | - M Baraldés Rovira
- Servicio de Neurología, Hospital Universitario Arnau de Vilanova, Lleida, España
| | - R Sivera Mascaró
- Servicio de Neurología, Hospital Francesc de Borja, Gandía, España
| | - E Cubo Delgado
- Servicio de Neurología, Hospital Universitario de Burgos, Burgos, España
| | | | - F Vázquez Sánchez
- Servicio de Neurología, Hospital Universitario de Burgos, Burgos, España
| | | | | | | | - C Labandeira Guerra
- Servicio de Neurología, Hospital Universitario Álvaro Cunqueiro, Vigo, España
| | - B Alemany Perna
- Servicio de Neurología, Hospital Universitario Josep Trueta, Girona, España
| | - A Carvajal Hernández
- Servicio de Neurología, Hospital Universitario Virgen de las Nieves, Granada, España
| | | | | | - N Caballol Pons
- Sección de Neurología, Hospital Moisés Broggi, Sant Joan Despí, Barcelona, España
| | - A Ávila Rivera
- Servicio de Neurología, Hospital General ĹHospitalet, Barcelona, España
| | | | - R Lobato Rodríguez
- Sección de Neurología, Hospital Universitario Infanta Sofía, Madrid, España
| | | |
Collapse
|
3
|
Arias Merino G, Sánchez Díaz G, Villaverde-Hueso A, Posada de la Paz M, Alonso Ferreira V. Mortality Statistics and their Contribution to Improving the Knowledge of Rare Diseases Epidemiology: The Example of Hereditary Ataxia in Europe. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2017; 1031:521-533. [PMID: 29214590 DOI: 10.1007/978-3-319-67144-4_28] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Official mortality statistics provide population-based data and serve to improve epidemiological knowledge of rare diseases (RDs), by helping with the description of the natural history of the disease. They are an important complement of registries and estimates of disease burden and costs. At the same time, they heighten both the visibility of these diseases and the interest in their study and the search for treatments that may increase survival. This chapter contains a European analysis of hereditary ataxia mortality, which considers the time trend in different countries and the geographical variability in risk of death. Despite the limitations of applying this data source to RDs, mortality statistics share criteria which facilitate international comparisons and are of great utility for obtaining sufficiently uniform and robust time series for analysis of low-prevalence diseases.
Collapse
Affiliation(s)
- Greta Arias Merino
- Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III, Madrid, Spain
| | - Germán Sánchez Díaz
- Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III, Madrid, Spain
| | - Ana Villaverde-Hueso
- Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III, Madrid, Spain.,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain
| | | | - Verónica Alonso Ferreira
- Instituto de Investigación de Enfermedades Raras (IIER), Instituto de Salud Carlos III, Madrid, Spain. .,Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Madrid, Spain.
| |
Collapse
|
4
|
Sánchez-López C, Perestelo-Pérez L, Escobar A, López-Bastida J, Serrano-Aguilar P. Health-related quality of life in patients with spinocerebellar ataxia. NEUROLOGÍA (ENGLISH EDITION) 2017. [DOI: 10.1016/j.nrleng.2015.09.002] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
5
|
Sánchez-López CR, Perestelo-Pérez L, Escobar A, López-Bastida J, Serrano-Aguilar P. Health-related quality of life in patients with spinocerebellar ataxia. Neurologia 2015; 32:143-151. [PMID: 26541695 DOI: 10.1016/j.nrl.2015.09.002] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 08/21/2015] [Accepted: 09/02/2015] [Indexed: 10/22/2022] Open
Abstract
INTRODUCTION The progressive deterioration of patients with spinocerebellar ataxia (SCA) has a major impact on their health-related quality of life (HRQOL). This study evaluates HRQOL in a sample of patients diagnosed with SCA and aims to estimate the predictive ability of a set of sociodemographic variables for the different dimensions of the General Health Questionnaire. METHODS A total of 80 patients diagnosed with SCA were assessed using a sociodemographic questionnaire and the SF-36 General Health Questionnaire. The sociodemographic variables studied were sex, age, presence of a carer, employment status, and time elapsed from diagnosis of the disease. RESULTS The 8 subscales of the SF-36 show positive and significant correlations to one another. Mean scores obtained on each SF-36 subscale differ between women and men, although this difference is significant only on the general health subscale, with men scoring higher than women. We found significant age differences on the vitality and social function subscales, with higher scores among younger patients (< 34 years). The variable 'presence of a carer' accounts for most of the total variance of the questionnaire. CONCLUSIONS The SF-36 is a valid and useful instrument for evaluating HRQOL in patients diagnosed with SCA. Presence of a carer seems to be a determinant of self-perceived quality of life in these patients.
Collapse
Affiliation(s)
- C R Sánchez-López
- Facultad de Psicología, Universidad de La Laguna, Tenerife, Santa Cruz de Tenerife, España
| | - L Perestelo-Pérez
- Servicio de Evaluación del Servicio Canario de la Salud, Tenerife, Santa Cruz de Tenerife, España; Red de Investigación en Servicios Sanitarios en Enfermedades Crónicas (REDISSEC), Tenerife, Santa Cruz de Tenerife, España; Centro de Investigaciones Biomédicas de Canarias (CIBICAN), Tenerife, Santa Cruz de Tenerife, España.
| | - A Escobar
- Red de Investigación en Servicios Sanitarios en Enfermedades Crónicas (REDISSEC), Tenerife, Santa Cruz de Tenerife, España; Unidad de Investigación, Hospital de Basurto, Bilbao, Vizcaya, España
| | - J López-Bastida
- Red de Investigación en Servicios Sanitarios en Enfermedades Crónicas (REDISSEC), Tenerife, Santa Cruz de Tenerife, España; Universidad de Castilla La Mancha, Talavera de la Reina, Toledo, España
| | - P Serrano-Aguilar
- Servicio de Evaluación del Servicio Canario de la Salud, Tenerife, Santa Cruz de Tenerife, España; Red de Investigación en Servicios Sanitarios en Enfermedades Crónicas (REDISSEC), Tenerife, Santa Cruz de Tenerife, España; Centro de Investigaciones Biomédicas de Canarias (CIBICAN), Tenerife, Santa Cruz de Tenerife, España
| |
Collapse
|
6
|
Ruano L, Melo C, Silva MC, Coutinho P. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology 2014; 42:174-83. [PMID: 24603320 DOI: 10.1159/000358801] [Citation(s) in RCA: 398] [Impact Index Per Article: 39.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2013] [Accepted: 01/17/2014] [Indexed: 01/11/2023] Open
Abstract
BACKGROUND Hereditary cerebellar ataxias (HCA) and hereditary spastic paraplegias (HSP) are two groups of neurodegenerative disorders that usually present with progressive gait impairment, often leading to permanent disability. Advances in genetic research in the last decades have improved their diagnosis and brought new possibilities for prevention and future treatments. Still, there is great uncertainty regarding their global epidemiology. SUMMARY Our objective was to assess the global distribution and prevalence of HCA and HSP by a systematic review and meta-analysis of prevalence studies. The MEDLINE, ISI Web of Science and Scopus databases were searched (1983-2013) for studies performed in well-defined populations and geographical regions. Two independent reviewers assessed the studies and extracted data and predefined methodological parameters. Overall, 22 studies were included, reporting on 14,539 patients from 16 countries. Multisource population-based studies yielded higher prevalence values than studies based primarily on hospitals or genetic centres. The prevalence range of dominant HCA was 0.0-5.6/10(5), with an average of 2.7/10(5) (1.5-4.0/10(5)). Spinocerebellar ataxia type 3 (SCA3)/Machado-Joseph disease was the most common dominant ataxia, followed by SCA2 and SCA6. The autosomal recessive (AR) HCA (AR-HCA) prevalence range was 0.0-7.2/10(5), the average being 3.3/10(5) (1.8-4.9/10(5)). Friedreich ataxia was the most frequent AR-HCA, followed by ataxia with oculomotor apraxia or ataxia-telangiectasia. The prevalence of autosomal dominant (AD) HSP (AD-HSP) ranged from 0.5 to 5.5/10(5) and that of AR-HSP from 0.0 to 5.3/10(5), with pooled averages of 1.8/10(5) (95% CI: 1.0-2.7/10(5)) and 1.8/10(5) (95% CI: 1.0-2.6/10(5)), respectively. The most common AD-HSP form in every population was spastic paraplegia, autosomal dominant, type 4 (SPG4), followed by SPG3A, while SPG11 was the most frequent AR-HSP, followed by SPG15. In population-based studies, the number of families without genetic diagnosis after systematic testing ranged from 33 to 92% in the AD-HCA group, and was 40-46% in the AR-HCA, 45-67% in the AD-HSP and 71-82% in the AR-HSP groups. KEY MESSAGES Highly variable prevalence values for HCA and HSP are reported across the world. This variation reflects the different genetic make-up of the populations, but also methodological heterogeneity. Large areas of the world remain without prevalence studies. From the available data, we estimated that around 1:10,000 people are affected by HCA or HSP. In spite of advances in genetic research, most families in population-based series remain without identified genetic mutation after extensive testing. © 2014 S. Karger AG, Basel.
Collapse
Affiliation(s)
- Luis Ruano
- Hospital de São Sebastião, CHEDV, Santa Maria da Feira, Portugal
| | | | | | | |
Collapse
|